Back to Results

Grifols SA ADR (GIKLY)

Grifols, S.A. is a Spanish healthcare company focused on plasma-derived medicines and related healthcare solutions. Through its subsidiaries, the group develops, produces, and markets therapies and products used in immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology. Its activities are organized into four segments: Biopharma, Diagnostic, Bio Supplies, and Others.

The company also supplies diagnostic testing equipment, reagents, transfusion medicine products, clinical diagnostics, and testing services. In addition, it provides biological materials and intermediate plasma products to pharmaceutical, biotechnology, and life-science customers, along with hospital solutions such as intravenous therapies, clinical nutrition, automation systems, and medical devices for several specialized care areas. Grifols was founded in 1909 and is headquartered in Barcelona, Spain.

The security listed under OTC Markets is an ADR, representing depositary receipt exposure to the company’s common stock rather than an ordinary operating share on the local exchange.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-GIKL.Y
$6.26
22.7% Upside
Undervalued
—
—
—
Great
—
—
0.11
1.5%
July 28, 2026
13.6x
1.0x
0.8x
6.51 B
19.657 B
54.4%
61.4%
7.1
30.8%
181.4%
Send a message
Valuation • Fair Value

Grifols SA ADR (OTC-GIKL.Y) Fair Value by Valuation Model

Compare the primary fair value estimate for Grifols SA ADR (OTC-GIKL.Y) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$6.26

Estimated upside of 22.7% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$5.33

Discounted cash flow valuation reference.

Ben Graham Formula Value

$4.21

Classic Ben Graham valuation formula reference.

DDM Fair Value

$6.29

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$6.86

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Grifols SA ADR (OTC-GIKL.Y) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Grifols SA ADR (OTC-GIKL.Y)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

8.597 B

Current operating scale indicator.

Revenue Forecast

8.781 B

Forward revenue estimate.

EBITDA

1.937 B

Current operating profitability reference.

EBITDA Forecast

2.185 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Grifols SA ADR (OTC-GIKL.Y) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Grifols SA ADR (OTC-GIKL.Y)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

-2.68

No elevated caution signal from this screen.

Altman Z-Score

7.1

Relatively strong balance-sheet zone.

FCF / Net Income

181.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Grifols SA ADR (OTC-GIKL.Y). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Grifols SA ADR (OTC-GIKL.Y)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

July 28, 2026

Days to Earnings

7

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

1.5%

Income yield reference.

Upcoming Dividend

0.11

Upcoming distribution amount.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

30.8%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Grifols SA ADR (OTC-GIKL.Y), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Grifols SA ADR (OTC-GIKL.Y) Stock Forecast & Technical Outlook

Review Grifols SA ADR (OTC-GIKL.Y) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Grifols SA ADR (OTC-GIKL.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Grifols SA ADR (OTC-GIKL.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Grifols SA ADR (OTC-GIKL.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Grifols SA ADR (OTC-GIKL.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Grifols SA ADR (OTC-GIKL.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Grifols SA ADR (OTC-GIKL.Y)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Grifols SA ADR (OTC-GIKL.Y) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

Grifols SA ADR (OTC-GIKL.Y) Stock FAQ

Quick answers about Grifols SA ADR (OTC-GIKL.Y) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$6.26
Estimated upside 22.7%
Valuation Rating
Undervalued
Estimated upside of 22.7%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Great
Current financial-health read

The current fair value estimate for Grifols SA ADR (OTC-GIKL.Y) is $6.26. This implies an estimated upside of 22.7% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 22.7% versus the current market price.

An analyst price target for Grifols SA ADR (OTC-GIKL.Y) is not currently available in the latest data file.

The current financial health read for Grifols SA ADR (OTC-GIKL.Y) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Grifols SA ADR (OTC-GIKL.Y) is July 28, 2026.

Based on the current data, dividend yield is 1.5%, upcoming dividend amount is 0.11.

The current P/E ratio listed for Grifols SA ADR (OTC-GIKL.Y) is 13.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Grifols SA ADR is 6.51 B.

The current enterprise value listed for Grifols SA ADR is 19.657 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Grifols SA ADR is OTC-GIKL.Y, and the stock is listed on OTC Markets.

Grifols SA ADR (OTC-GIKL.Y) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Grifols SA ADR is 54.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Grifols SA ADR is 61.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on OTC Markets View more

CSL Ltd (CSLLY) CSL Ltd (CSLLY)
Swedish Orphan Biovitrum AB ADR (BIOV.F) Swedish Orphan Biovitrum AB ADR (BIOV.F)
Bavarian Nordic A/S ADR (BVNRY) Bavarian Nordic A/S ADR (BVNRY)
Mesoblast Ltd (MEOBF) Mesoblast Ltd (MEOBF)
Galapagos NV (GLPGF) Galapagos NV (GLPGF)
Pharma Mar SAU (PHMMF) Pharma Mar SAU (PHMMF)
Biogaia AB ADR (BIOGY) Biogaia AB ADR (BIOGY)
Kuros Biosciences AG (CSBTF) Kuros Biosciences AG (CSBTF)
Clinuvel Pharmaceuticals Ltd (CLVLF) Clinuvel Pharmaceuticals Ltd (CLVLF)
Northwest Biotherapeutics Inc (NWBO) Northwest Biotherapeutics Inc (NWBO)
Spectral Med Inc (EDTXF) Spectral Med Inc (EDTXF)
Cytodyn Inc (CYDY) Cytodyn Inc (CYDY)
Innate Pharma (IPHYF) Innate Pharma (IPHYF)
Vaxart Inc (VXRT) Vaxart Inc (VXRT)
CapForce Inc (CFOR) CapForce Inc (CFOR)
Adocia SA ADR (ADOCY) Adocia SA ADR (ADOCY)
Nuo Therapeutics Inc (AURX) Nuo Therapeutics Inc (AURX)
Cell Source Inc (CLCS) Cell Source Inc (CLCS)
Protext Mobility Inc (TXTM) Protext Mobility Inc (TXTM)
MindMaze Therapeutics Holding SA (RLFTF) MindMaze Therapeutics Holding SA (RLFTF)
Sernova Corp (SEOVF) Sernova Corp (SEOVF)
Microbix Biosystems Inc. (MBXBF) Microbix Biosystems Inc. (MBXBF)
Resverlogix Corp. (RVXCF) Resverlogix Corp. (RVXCF)
Medicenna Therapeutics Corp (MDNAF) Medicenna Therapeutics Corp (MDNAF)